The economics of sexually transmitted infections

Sexually Transmitted Diseases

Volumn 33, Issue 10 SUPPL., 2006, Pages

  Over, A Mead ^a   Aral, Sevgi O ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD BANK   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSTATISTICS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; EDITORIAL; HEALTH CARE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; QUALITY OF LIFE; SEXUALLY TRANSMITTED DISEASE; SIMULATION; SOCIAL ASPECT;

EID: 33749039166     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000237877.45179.01     Document Type: Editorial

References (21)

1. Briscoe. Am J Public Health.
2. Over et al. Am J Trop Health Hyg.
3. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
4. Heckman JJ, Ichimura H, Todd P. Matching as an econometric evaluation estimator. Review of Economic Studies 1998; 65:261-294.
5. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91:444-455.
6. Foster EM. Propensity score matching: An illustrative analysis of dose response. Med Care 2003; 41:1183-1192.
7. Yorke JA, Hethcote HW, Nold A. Dynamics and control of the transmission of gonorrhea. Sex Transm Dis 1978; 5:51-57.
8. Hethcote HW, Yorke JA. Gonorrhea transmission dynamics and control. Lecture Notes in Biomathematics. New York: Springer, 1984:56.
9. Over M, Piot P. HIV infection and sexually transmitted diseases. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993:445-529.
10. Over M, Piot P. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: Public health importance and priorities for resource allocation. J Infect Dis 1996; 174(suppl 2):S162-S175.
11. Klarman HE. Syphilis control programs. In: Dorfman R, ed. Measuring Benefits of Government Investments. Washington, DC: Brookings Institution, 1965:367-414.
12. Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993.
13. Gift TL, et al. The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims. Sex Transm Dis 2006; 33 Supplement:S84-S88.
14. Vickerman P, et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 2006; 33 Supplement:S89-S102.
15. Gift TL, et al. A cost-effectiveness evaluation of a jail-based chlamydia screening program for men and its impact on their partners in community. Sex Transm Dis 2006; 33 Supplement:S103-S110.
16. Terris-Prestholt F, et al. The role of community acceptance over time for costs of HIV and STI prevention interventions: Analysis of the Masaka Intervention Trial, Uganda, 1996-1999. Sex Transm Dis 2006; 33 Supplement:S111-S116.
17. Blandford JM, et al. Productivity losses attributable to untreated infection with Chlamydia trachomatis and to associated pelvic inflammatory disease in reproductive-age women. Sex Transm Dis 2006; 33 Supplement:S117-S121.
18. Vickerman P, et al. Are targeted HIV prevention activities still cost-effective in high prevalence settings? Results from an STI treatment intervention for sex workers in South Africa. Sex Transm Dis 2006; 33 Supplement:S122-S132.
19. Terris-Prestholt F, et al. From trial intervention to scale-up: Costs of an adolescent sexual health program in Mwanza, Tanzania. Sex Transm Dis 2006; 33 Supplement:S133-S139.
20. Chesson H. The estimated effectiveness and cost-effectiveness of federally-funded prevention efforts on gonorrhea rates in the United States, 1971-2003, under various assumptions about the impact of prevention funding. Sex Transm Dis 2006; 33 Supplement:S140-S144.
21. Over M, et al. Antiretroviral therapy and HIV prevention in India: Modeling costs and consequences of policy options. Sex Transm Dis 2006; 33 Supplement:S145-S152.